Search
for

    Sort by

    Community Join

    900-930 / 1000+ results

      community Estimate of GT20029 on the grey market?

      in Technology  9 upvotes 2 years ago
      The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

      community Aminexil, Nanoxidil, Stemoxydine and Kopexil. Anyone use them?

      in Question  1 upvotes 9 years ago
      Aminexil, nanoxidil, stemoxydine, and kopexil are discussed as alternatives to minoxidil for hair growth, with concerns about dependence. Minoxidil is noted for its effectiveness in transitioning hair growth phases, but dependence is mainly linked to androgenic alopecia.

      community Opinions- AGA options and pregnancy

      in Female  7 upvotes 1 year ago
      A user with Androgenetic Alopecia is seeking advice on hair growth treatments while planning for pregnancy. Current routine includes LaserCap, Nizoral Shampoo, scalp massage, The Ordinary Multi Peptide Serum, vitamin D, prenatal vitamins, and SEEN shampoo.

      community 26/F - Lots of stuff going on - Pics inside.

       5 upvotes 11 years ago
      A 26 year old female with PCOS who has been dealing with hair loss for several years, despite managing her hormones and taking vitamins. She has tried various treatments such as Nizoral, Minoxidil, Pyrithione zinc, coal tar and salicylic acid to no avail. The user is looking for advice on what else they can do to stop their hair loss.

      community PP405 (Non) Update - Feb 2025

      in Research/Science  34 upvotes 1 year ago
      The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

      community Clascoterone - what we have right now

      in Research/Science  23 upvotes 2 months ago
      Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

      community currently active protocols, working so far

      in Update 3 years ago
      The conversation is about a person's hair loss treatment routine, which includes Metformin, sleep in darkness, avoiding EMF at night, Nizoral, Dermarolling, Castor oil, and Collagen. They have observed less hair shedding and increased hair volume.

      community Bryan johnson mail about his routine

      in Chat  64 upvotes 1 year ago
      A user shared their successful hair loss and gray hair reversal routine, which includes Minoxidil, Cetirizine HCl, Latanoprost, Dutasteride, Melatonin, Caffeine, Tretinoin, Vitamin D3, and Vitamin E. They also use a red light cap, oral Minoxidil, and are developing new treatments.

      community Hold up... CosmeRNA/SAMiRNA is actually coming real soon?

      in Technology  31 upvotes 3 years ago
      A user discovered CosmeRNA, a new hair loss treatment with clinical research backing, set to release soon. The conversation revolves around its potential effectiveness, cost, and how it compares to existing treatments like Minoxidil and Finasteride, with some users expressing hope for a side-effect-free option.

      community Two Shedding Cycles? Telogen effluvium or not?

      in Question  4 upvotes 6 years ago
      The user experienced significant hair loss after extended fasting, initially thought to be Telogen Effluvium, but later suspected male pattern baldness. They tried finasteride briefly but stopped due to concerns about side effects, and are unsure if the hair loss is due to Telogen Effluvium or another cause.

      community Another blow to the cursed baldness

      in Research/Science  91 upvotes 7 months ago
      A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

      community cb-03-01 research chem (winlevi/clascoterone cream)

      in Technology  3 upvotes 2 years ago
      The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

      community Pelage Recruiting Now for Phase 2

      in Research/Science  11 upvotes 1 year ago
      Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

      community When is GT20029 going to come out?

      in Research/Science  35 upvotes 1 year ago
      The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.

      community A concern regarding the upcoming androgen degrader drug GT20029

      in Chat  12 upvotes 1 year ago
      GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

      community PP405 bandwagon, time to resume the hype train.

      in Treatment  165 upvotes 8 months ago
      PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.